Login

NON-SUBSCRIBER OPTIONS
FREE TRIAL   |   NEWSSTAND

Home

GET 30 DAYS FREE

The next health policy debate begins now, and the future direction of health reform seems more uncertain than ever. Now is the time to take advantage of the detailed, forward-looking reporting that only Inside Health Policy delivers.

Sign up for 30 days of no-obligation access for all the essential news during this critical time.

Top Story

Canceling Mandatory Demos Would Have Small Impact On Doc-Pay System

CMS' proposal to cancel mandatory bundling demonstrations would have a small impact on the new Medicare physician pay system, provider lobbyists say, because although that system aims to get doctors to join alternative pay models, the pay models CMS wants to cancel are designed for hospitals.

Voluntary Bundled Pay Participation Expected To Expand Among Large Hospital Systems

Latest News

President Donald Trump signed Friday (Aug. 18) the FDA Reauthorization Act of 2017, a White House spokesperson tells Inside Health Policy.

Concerns over Risk Evaluation and Mitigation Strategies (REMS) abuse are largely misinformed and current reform proposals would create liability and diversion concerns for brand drug makers, an alliance of pharmaceutical companies and patient advocacy organizations argues in recent comments to FDA.

The nation's largest state-based exchange said Thursday (Aug. 17) that it will hold off on finalizing 2018 premium increases until Sept. 30 due to ongoing federal uncertainty, including the potential that Congress will fund the ACA’s cost-sharing reductions.

The Department of Justice announced Thursday (Oct. 17) an EpiPen settlement of $465 million, which is the same amount DOJ denied having settled on last October when EpiPen maker Mylan announced the deal.

The Health Resources and Services Administration proposed another delay, this time until July 2018, of a rule on the 340B drug discount program that sets ceiling prices and civil monetary penalties as the agency considers changing the regulation.

In anticipation of what could be the most expensive cancer drug to date, the Patients for Affordable Drugs launched Thursday (Aug. 17) a national campaign demanding that Novartis factor in the considerable taxpayer investment in early research of the company's CAR-T cell therapy, which is at the forefront of individually tailored medicines that could cure certain cancers.

Answering the calls of congressional Republicans, FDA is siding with the food industry in a lawsuit seeking to stop New York City's menu labeling regulation from being enforced until FDA implements its national standard.